A Phase 3 interventional study of Plecanatide in Irritable Bowel Syndrome, sponsored by Bausch Health Americas, Inc.. Completed at 204 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-08-18.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc. — none open to participants now, none under way, none of them phase 3. Irritable Bowel Syndrome · Bausch Health Companies Inc..
Among the 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc., this one has the largest enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 9th registered.
1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.
Browse Irritable Bowel Syndrome studies →None of the 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc. is open now. The open studies under Irritable Bowel Syndrome, anywhere →
Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2016.
This study's enrollment of 2,272 is above the median of 70 across 898 interventional studies indexed under Irritable Bowel Syndrome.
Median enrollment 337 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Irritable Bowel Syndrome by Bausch Health Companies Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multi-center, open-label, long-term safety study
This is a phase 3, multicenter, open-label, long-term safety and tolerability study of 6 mg daily dose of plecanatide administered orally. Patients who are Study Completers or Eligible Screen Failures whose eligibility is confirmed at the end of their participation in the double-blind plecanatide studies SP304203-04 or SP304203-05 will be enrolled.
Beginning on Day 1, patients will take one (1) plecanatide 6.0 mg tablet in the clinic and thereafter every morning with approximately 240 mL (8 ounces) of liquid, with or without meals.
Safety and tolerability assessments and patients' self-assessment of disease severity will be performed according to the Schedule of Assessments.
Patients who discontinue early from the study will undergo an Early Withdrawal (EW) visit within 5 days after stopping study drug.
Inclusion Criteria:
Patients with documented diagnosis of IBS-C who:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plecanatide 6.0 mg tablets
Drug: Plecanatide
Number of Participants With Treatment Related Adverse Events.
Number of participants with adverse events with evidence to suggest a causal relationship between treatment and study drug.
Time frame: up to 53 weeks
Eligible subjects with IBS-C from SP304203-04 (NCT02387359), SP304203-05 (NCT02493452), and SP304-20212 (NCT01722318), and subjects that did not previously participate in any plecanatide study, were enrolled.
| Milestone | Plecanatide |
|---|---|
| Started | 2272 |
| Completed | 1842 |
| Not completed | 430 |
| Withdrew: Adverse event | 97 |
| Withdrew: Death | 1 |
| Withdrew: Lack of efficacy | 39 |
| Withdrew: Lost to follow-up | 101 |
| Withdrew: Non-compliance with study drug | 15 |
| Withdrew: Physician decision | 6 |
| Withdrew: Pregnancy | 6 |
| Withdrew: Protocol violation | 18 |
| Withdrew: Withdrawal by subject | 136 |
| Withdrew: Non-compliance with visits | 6 |
| Withdrew: Site closure | 4 |
| Withdrew: Subject moved | 1 |
Number of participants with adverse events with evidence to suggest a causal relationship between treatment and study drug.
| Participants | Plecanatide |
|---|---|
| Number of Participants With Treatment Related Adverse Events. | 205 |
Collected over Up to 53 weeks.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Plecanatide | 1/2,272 (0%) | 45/2,272 (2%) | 341/2,272 (15%) |
| Event | Plecanatide |
|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 6/2272 |
| Aspartate Aminotransferase IncreasedInvestigations | 5/2272 |
| DiverticulitisInfections and infestations | 3/2272 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 2/2272 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 2/2272 |
| Non-Cardiac Chest PainGeneral disorders | 2/2272 |
| Liver Function Test AbnormalInvestigations | 1/2272 |
| Transaminases IncreasedInvestigations | 1/2272 |
| Bacterial PyelonephritisInfections and infestations | 1/2272 |
| CellulitisInfections and infestations | 1/2272 |
| Event | Plecanatide |
|---|---|
| DiarrhoeaGastrointestinal disorders | 153/2272 |
| Upper Respiratory Tract InfectionInfections and infestations | 43/2272 |
| Urinary Tract InfectionInfections and infestations | 34/2272 |
| NasopharyngitisInfections and infestations | 34/2272 |
| NauseaGastrointestinal disorders | 29/2272 |
| HeadacheNervous system disorders | 25/2272 |
| SinusitisInfections and infestations | 23/2272 |
| Age, Continuous(years) | Plecanatide |
|---|---|
| Mean | 45.3 ± 14.18 |
| Sex: Female, Male(Participants) | Plecanatide |
|---|---|
| Female | 1744 |
| Male | 528 |
| Race (NIH/OMB)(Participants) | Plecanatide |
|---|---|
| American Indian or Alaska Native | 4 |
| Asian | 55 |
| Native Hawaiian or Other Pacific Islander | 4 |
| Black or African American | 504 |
| White | 1692 |
| More than one race | 13 |
| Unknown or Not Reported | 0 |
| Body Mass Index(kilograms per meters squared) | Plecanatide |
|---|---|
| Mean | 28.4 ± 4.87 |
Showing the first 100 of 204 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jan 2016, a primary completion of May 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 3 years 3 months after primary completion. A results delay was requested in May 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bausch Health Americas, Inc. →